Revolution Medicines, Inc.

NASDAQ:RVMD

Biotechnology

Healthcare
$159.82 +2.28%

+$3.60 today

Market cap
$34.57B
Beta
1.41
P/E (TTM)
-23.3
EPS (TTM)
-$6.92
52W Low $34.00High $166.50

Volume 2.34M

Average 3.10M

RVMD Operating Margin

Operating income as a percentage of revenue, showing the profitability of core operations.

Revolution Medicines, Inc.NASDAQ: RVMD

Operating Margin · Q2 FY2026 · quarter ended Jun 2026

Operating margin not reported for Q2 FY2026

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
—— QoQ
Last fiscal yearDec 2025
—— YoY
LTMJun 2026
—— YoY
Operating Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3 years———
5 years——
10 years——

Operating Margin history

Percent of revenue · from the income statement

Latest · FY2023
-4207.1%
Year-over-year change
-3477.1pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Margin vs competitors

How RVMD compares with its peers on the latest reported figures

RVMD Competitors Peer median
Operating Margin for RVMD and competitors
Company Period LTM level YoY 3-year change
NRIXNurix Therapeutics, Inc.LTM Aug 202641.3% +360.6 pp+135.8 pp
BDTXBlack Diamond Therapeutics, Inc.FY202528.4% ——
IDYAIDEAYA Biosciences, Inc.LTM Mar 2026-81.4% +5066.4 pp+49.9 pp
TNGXTango Therapeutics, Inc.FY2025-178.4% +167.7 pp+268.4 pp
VSTMVerastem, Inc.LTM Mar 2026-344.6% +966.2 pp+2259.3 pp
GLUEMonte Rosa Therapeutics, Inc.LTM Mar 2026-345.2% -343.9 pp—
RLAYRelay Therapeutics, Inc.LTM Jun 2026-2999.4% +1106.2 pp+19699.3 pp
RVMDRevolution Medicines, Inc.FY2025— ——
ERASErasca, Inc.FY2025— ——
ELVNEnliven Therapeutics, Inc.FY2025— ——
ORICORIC Pharmaceuticals, Inc.FY2025— ——
Peer median (excluding RVMD) -178.4%+663.4 pp+268.4 pp

Competitors are the stored peer set for RVMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue29.39M35.38M11.58M00
Cost of Revenue000016.56M
Gross Profit29.39M35.38M11.58M0(16.56M)
Gross Margin100.0%100.0%100.0%——
Research & Development186.95M253.07M423.14M592.23M978.68M
Selling, General & Admin30.45M40.59M75.62M97.3M187.13M
Operating Expenses217.4M293.66M498.77M689.52M1.17B
Depreciation & Amortization7.33M9.66M9.31M11.82M16.56M
EBITDA(179.75M)(239.47M)(430.28M)(589.02M)(1.09B)
EBITDA Margin-611.6%-676.8%-3715.7%——
Operating Income(188.01M)(258.28M)(487.19M)(689.52M)(1.18B)
Operating Margin-639.7%-730.0%-4207.1%——
Interest Income929K9.15M47.48M86.88M90.69M
Interest Expense12K0303K024.23M
Other Income / Expenses917K9.15M47.29M88.68M51.07M
Income Before Tax(187.09M)(249.13M)(439.89M)(600.85M)(1.13B)
Pre-Tax Margin-636.6%-704.1%-3798.7%——
Income Tax Expense0(420K)(3.52M)(753K)0
Net Income(187.09M)(248.71M)(436.37M)(600.09M)(1.13B)
Net Margin-636.6%-703.0%-3768.3%——
EPS (Basic)(2.47)(3.08)(3.86)(3.58)(5.95)
EPS (Diluted)(2.47)(3.08)(3.86)(3.58)(5.95)
Weighted Avg Shares72.81M80.63M113.15M167.74M190.13M
Weighted Avg Shares (Diluted)72.81M80.63M113.15M167.74M190.13M

Revolution Medicines, Inc.

NASDAQ:RVMD

Intrinsic Alpha fair value

Locked

Current Price

$159.82

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.